Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

Introduction: The phase 3 DUPLEX trial is evaluating sparsentan, a novel, nonimmunosuppressive, single-molecule dual endothelin angiotensin receptor antagonist, in patients with focal segmental glomerulosclerosis (FSGS). Methods: DUPLEX (NCT03493685) is a global, multicenter, randomized, double-blin...

Descripció completa

Dades bibliogràfiques

Autors principals:	Howard Trachtman, Jai Radhakrishnan, Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, Hiddo J.L. Heerspink, Irene L. Noronha, Vlado Perkovic, Brad Rovin, Hernán Trimarchi, Muh Geot Wong, Alex Mercer, Jula Inrig, William Rote, Ed Murphy, Patricia W. Bedard, Sandra Roth, Stewart Bieler, Radko Komers
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-04-01
Col·lecció:	Kidney International Reports
Matèries:	dual endothelin angiotensin receptor antagonist focal segmental glomerulosclerosis pediatric race randomized controlled clinical trial sparsentan
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2468024924000421
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!